Eli Lilly
Eli Lilly and Company is an American pharmaceutical company, founded in 1876, that is known for its contributions to the development of various medications across multiple therapeutic areas, including diabetes, oncology, and immunology. The company has gained recognition for its diabetes treatment, Mounjaro, which is part of the GLP-1 receptor agonist class. Eli Lilly is committed to improving patient outcomes through innovative products and has a strong focus on research and development.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Ireland | 1 | 5.00 | 0.09% | +0% | 5,030,000 | 4,688 | $5,100 | 5$ |
| Totals | 1 | 5,030,000 | 4,688 | $5,100 | 5$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Ireland:
Eli Lilly is a company that is undertaking new investment in Ireland but may move production back to the US.
5
United States:
The Trump administration recently negotiated a deal with Eli Lilly and Novo Nordisk to provide their weight loss drugs to Medicare at a discounted rate.
6
Saudi Arabia:
Eli Lilly conducted a clinical trial for their experimental drug 'Retatrutide'.
8
Romania:
Eli Lilly has presented record results for its new obesity medication, showing weight loss of up to 28.7% in the completed study.
9
Denmark:
Eli Lilly is mentioned as a competitor to Novo Nordisk in the weight loss medication market.
5
Denmark:
Novo Nordisk faces strong competition from American Eli Lilly.
5
Denmark:
Eli Lilly's stock increased by 0.7 percent and has risen 15 percent over the last four days.
7
Switzerland:
Eli Lilly is reportedly negotiating a similar agreement for drug pricing.
6
Slovenia:
American Eli Lilly has significantly impacted the market with its own weight loss drugs.
6
Slovenia:
Eli Lilly is a pharmaceutical giant that announced the results of a clinical study for its obesity pill, orforglipron.
5